Santiago M. Thibaud

Hematology

1470 Madison Ave
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.

Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.

Journal: Bone marrow transplantation

Published: January 21, 2026

Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.

Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.

Journal: JCI insight

Published: December 23, 2025

Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility.

Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility.

Journal: Blood reviews

Published: November 24, 2025

Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Journal: Blood advances

Published: August 13, 2025

Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.

Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 01, 2025

Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma.

Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma.

Journal: Bone marrow transplantation

Published: November 26, 2024

FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk.

FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk.

Journal: Seminars in hematology

Published: October 07, 2024

Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.

Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.

Journal: Blood advances

Published: July 16, 2024

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.

Journal: Blood advances

Published: June 28, 2024

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma.

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma.

Journal: Blood neoplasia

Published: February 29, 2024

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.

Journal: Blood advances

Published: December 26, 2023

Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.

Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.

Journal: Blood cancer discovery

Published: October 06, 2023

Showing 1-12 of 28

Last Updated: 09/26/2026